Purpose: Azithromycin and tetracyclines are commonly prescribed in the United States for the treatment of meibomian gland dysfunction (MGD). The efficacy of these antibiotics has been believed to be their antiinflammatory and antibacterial actions, which suppress MGDassociated posterior blepharitis and growth of lid bacteria. However, we recently discovered that azithromycin can act directly on human meibomian gland epithelial cells (HMGECs) to stimulate their function. In this study, we sought to determine whether tetracycline antibiotics can duplicate this azithromycin effect.
M eibomian gland dysfunction (MGD), the leading cause of dry eye disease throughout the world, afflicts hundreds of millions of people and has no cure. 1, 2 In the United States, antibiotics such as azithromycin and tetracyclines -especially doxycycline, minocycline, and tetracycline-are widely used off-label in the treatment of MGD. 1 Therapeutic effects of these antibiotics were believed to be indirect, suppressing MGD-associated posterior blepharitis and bacterial lipase activity on the lid. 2 However, we recently discovered that azithromycin can act directly on human meibomian gland epithelial cells (HMGECs) to induce cholesterol, phospholipid, and lysosome accumulation, and ultimately a holocrine-like secretion. 3, 4 We hypothesize that this intracellular effect of azithromycin is due in large part to its cationic amphiphilic structure. 5 If our hypothesis is correct, then azithromycin's action on HMGECs is unique, and will not be duplicated by tetracyclines. To test this hypothesis, we compared the effects of azithromycin and tetracyclines on HMGEC differentiation and proliferation in defined conditions. 6, 7 We also determined the relative ability of these antibiotics to induce sterol regulatory element-binding protein 1 (SREBP-1) and cyclin B1, which are key regulators of lipogenesis and the cell cycle, respectively. 8, 9 MATERIALS AND METHODS Immortalized HMGECs were cultured in media that promote either proliferation (serum-free) or differentiation (serum-containing), according to published techniques. 6 Cells were treated with an ethanol vehicle, azithromycin (10 mg/mL; Santa Cruz Biotechnology, Dallas, TX), doxycycline (0.1-10 mg/mL; Sigma-Aldrich, St Louis, MO), minocycline (0.1-10 mg/mL; Sigma-Aldrich), or tetracycline (0.1-10 mg/mL; Sigma-Aldrich) for 5 days. These doses were selected based on our preliminary experiments with HMGECs and on their established safety in human corneal cells. 10, 11 Cell numbers were counted with a hemocytometer. Cellular neutral lipid and lysosome accumulation were evaluated with LipidTOX green neutral lipid stain (Life Technologies, Grand Island, NY) and LysoTracker Red DND-99 (Life Technologies). All experiments were repeated at least 3 times. Each experiment was performed in duplicate under the same conditions. Data from 1 representative experiment were used for quantitation. Eight random images were taken of each group on the same day with the same exposure time, and the whole cell area in each image was selected for the measurement of fluorescent intensities. The data show the mean fluorescence intensity of all the cells in each image, and the cell number was similar in all groups. Total cellular lipid composition was analyzed by high-performance thin-layer chromatography. 12 Each sample contained the same amount of cellular extract, and cell lysates were analyzed by immunoblot.
Membranes were incubated with antibodies specific for SREBP-1 (Santa Cruz, H-160, 1:500), cyclin B1 (Cell Signaling Technology, Danvers, MA; 1:500), or b-actin (Cell Signaling Technology, 1:10,000), followed by HRP-conjugated secondary antibodies (1:5000, Sigma-Aldrich). The fluorescence intensities of LipidTOX and LysoTracker, as well as immunoblot band intensities, were quantified using ImageJ.
For statistical evaluation, analysis of variance and Newman-Keuls multiple comparisons tests were performed with Prism 5 software (GraphPad Software, Inc, La Jolla, CA). 
RESULTS
Our results demonstrate that azithromycin's ability to stimulate the differentiation of HMGECs is unique and is not duplicated by doxycycline, minocycline, or tetracycline. Azithromycin, but not the other antibiotics, significantly enhanced the cellular accumulation of neutral lipid-containing lysosomes in these cells (Fig. 1) . In contrast, minocycline and tetracycline promoted the formation of small, nonlysosomal neutral lipid droplets. The differentiative actions of azithromycin were paralleled by an increased expression of SREBP-1, which appeared as a cluster of protein bands between 59 and 68 kDa 13 (Fig. 1) . We also found that azithromycin, but not the tetracycline antibiotics, significantly augmented cellular levels of free cholesterol, cholesterol esters, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylcholine, and decreased the content of triglycerides (Fig. 2) . By contrast, minocycline and tetracycline significantly increased the cellular triglyceride amounts.
All the antibiotics reduced cell proliferation when cultured in serum-free conditions, whereas only minocycline reduced cell numbers in serum-containing cultures (Fig. 3) . The antiproliferative effects of azithromycin, doxycycline and minocycline were associated with a significant decrease in cyclin B1 levels.
For these studies, we used azithromycin at a dose of 10 mg/mL and doxycycline, minocycline, and tetracycline at concentrations of 5 mg/mL. Our reasons were 3-fold. First, we had previously shown this azithromycin dosage to be optimal and clinically relevant. 3, 14, 15 Second, our preliminary studies demonstrated that the 10 mg/mL concentrations of doxycycline, minocycline, and tetracycline were very cytotoxic when cells were cultured in a serum-free medium. And third, our dose-response experiments (0.1, 0.5, 1.0, 3.0, and 5.0 mg/mL) showed that the 5 mg/mL levels were tolerable in both serum-free and serum-containing cultures.
DISCUSSION
Our study supports our hypothesis that the ability of azithromycin to promote the differentiation of HMGECs is unique and not duplicated by doxycycline, minocycline, or tetracycline. Azithromycin, but not the other antibiotics, significantly increased the cellular content of free cholesterol, cholesterol esters, phospholipids, lysosomes, and SREBP-1, a key transcription factor for lipogenesis. This azithromycininduced accumulation of neutral lipids occurred primarily within lysosomes. In contrast, minocycline and tetracycline augmented triglyceride levels and the formation of nonlysosomal lipid droplets. These results suggest that azithromycin, but not doxycycline, minocycline, or tetracycline, may be beneficial as a clinical treatment for stimulating HMGEC function.
The maturation of HMGECs involves the generation of lysosomes, the accumulation of lipids within these vesicles, and ultimately the release of lipid-laden contents by holocrine secretion. 7 Our previous research suggests that the capacity of azithromycin to stimulate this differentiation process is due to its cationic amphiphilic nature. 4 Cationic amphiphilic compounds are known to promote the propagation of lipidcontaining lysosomes, and especially the accumulation of phospholipids. 4, 16 Doxycycline, minocycline, and tetracycline do not possess this amphiphilic structure.
The tetracycline derivatives, however, were able to act directly on the HMGEC. These antibiotics, as well as azithromycin, all suppressed cellular proliferation in serumfree cultures. This "nonantibiotic" effect has also been observed in other cells, 17 and for azithromycin, doxycycline, and minocycline was accompanied by a decrease in cyclin B1, a regulator of G2/M transition and mitosis. 18 We also found that minocycline and tetracycline increased, whereas azithromycin decreased, intracellular levels of triglycerides. This stimulatory influence was associated with the formation of small nonlysosomal neutral lipid droplets. These actions of minocycline and/or tetracycline are analogous to those they induce in hepatic cells. 19, 20 Given our experimental findings, it is of interest that tetracycline derivatives reportedly relieve symptoms of patients with MGD. 21, 22 This response may be due to the antiinflammatory and antibacterial actions of these antibiotics, which may suppress the MGD-associated posterior blepharitis and growth of lid bacteria. 1 However, the additional lipid-promoting activity of azithromycin may account for its significantly greater efficacy, as compared with doxycycline, in alleviating the signs (ie, ocular surface staining and conjunctival redness) of MGD-associated evaporative dry disease. 22 
